Ryan Humiston retatrutide videos spark a lot of questions. Here's what the fitness creator has said, how the unapproved drug works, and the real risks.
Ryan Humiston is a fitness content creator known for high-volume training videos, and "ryan humiston retatrutide" searches come mostly from viewers trying to figure out whether he uses, sells, or endorses the drug. Retatrutide is an investigational triple-hormone-receptor agonist from Eli Lilly that is not FDA-approved and cannot be legally prescribed or sold for human use in the United States. There is no verified public record showing that Ryan Humiston prescribes retatrutide or sells it, and any product marketed with his name should be treated with skepticism.
What Is Retatrutide?
Retatrutide, developed under the code name LY3437943, is a once-weekly injectable drug that activates three hormone receptors at the same time.
- GLP-1 — slows stomach emptying and reduces appetite, the same pathway as semaglutide.
- GIP — the pathway targeted by tirzepatide, linked to improved insulin sensitivity.
- Glucagon — may increase energy expenditure and fat oxidation.
In a Phase 2 trial published in the New England Journal of Medicine in 2023, adults with obesity who received 12 mg weekly for 48 weeks lost an average of roughly 24% of their starting body weight. That result is larger than anything reported for approved obesity drugs in comparable trials.
Retatrutide is still being studied in the Phase 3 TRIUMPH program, and Eli Lilly has not announced a retatrutide brand name. Until the FDA completes its review, retatrutide remains an experimental compound.
Why Is "Ryan Humiston Retatrutide" Such a Common Search?
Fitness creators have become a primary source of drug and supplement information for lifters, and GLP-1 medications are among the most-discussed topics on those channels.
Humiston has built an audience around training intensity, nutrition, and bodybuilding culture, and viewers frequently ask about peptides, GLP-1 drugs, and fat-loss compounds in the comments. Discussing a drug on YouTube is not the same as using it, selling it, or recommending it to viewers.
Search interest also spikes when a creator films a reaction video, reads a study, or mentions that a client is using a compound. Those clips get clipped, reposted, and stripped of context, which is how a name becomes permanently attached to a drug in search results.
Does Ryan Humiston Own or Promote a Peptide Company?
Questions about the ryan humiston peptide company come from viewers who want to know whether he has a financial stake in a peptide or supplement brand. Fitness creators typically earn money through affiliate links, discount codes, sponsored segments, and brands they own outright.
There is no verified public information confirming that Humiston owns or operates a peptide company that sells retatrutide. If you see a creator's discount code on a research-chemical website, treat that code as an advertisement rather than a medical endorsement.
Retatrutide is not a supplement. It is an unapproved investigational drug, and no influencer's opinion changes its regulatory status.
How Retatrutide Compares With Other Weight-Loss Drugs
Anyone researching cagrilintide vs retatrutide vs tirzepatide is looking at three different mechanisms and three very different stages of development.
| Drug | Mechanism | FDA status | Reported weight loss |
|---|---|---|---|
| Retatrutide | GLP-1, GIP, and glucagon triple agonist | Investigational; not approved | About 24% at 48 weeks (12 mg, Phase 2) |
| Tirzepatide (Zepbound) | GIP and GLP-1 dual agonist | Approved for chronic weight management | About 21% at 72 weeks (SURMOUNT-1) |
| Semaglutide (Wegovy) | GLP-1 agonist | Approved for chronic weight management | About 15% at 68 weeks (STEP 1) |
| Cagrilintide | Amylin analog, studied with semaglutide as CagriSema | Investigational; not approved | About 23% at 68 weeks (CagriSema, REDEFINE-1) |
Those percentages come from separate trials with different populations, treatment durations, and dose-escalation schedules, so they are not direct head-to-head comparisons. Approved drugs can be prescribed today under medical supervision; retatrutide cannot.
Retatrutide Dosage and How Long It Takes to Work
The retatrutide dosage used in the Phase 2 trial started low and increased gradually to limit gastrointestinal side effects. Participants began at 1 mg or 2 mg per week and escalated over roughly 16 to 20 weeks to maintenance doses of 8 mg or 12 mg.
Many people also ask how long does retatrutide take to work. In the trial data, appetite changes often appeared within the first few weeks, measurable weight loss was usually visible by 4 to 8 weeks, and the largest reductions showed up between 24 and 48 weeks of continuous treatment.
Those numbers describe monitored trial volunteers. They are not a dosing guide, and self-administered doses from grey-market vials are not comparable.
Safety and the Research-Chemical Problem
Reported side effects in retatrutide trials were mostly gastrointestinal: nausea, vomiting, diarrhea, and constipation. Some participants also showed modest increases in resting heart rate.
- Retatrutide has no FDA approval, no approved label, and no standard dosing guidance.
- Compounds sold online as "retatrutide" are unregulated and may contain the wrong amount of drug, or no drug at all.
- Long-term safety data in humans do not exist yet, and Phase 3 results are still pending.
- People who are pregnant, breastfeeding, or managing other health conditions should not use unapproved injectables.
Anyone considering a GLP-1 medication should talk with a licensed healthcare professional about approved options such as semaglutide or tirzepatide.
The Bottom Line
Ryan Humiston is a fitness YouTuber, not a researcher, prescriber, or regulatory authority on retatrutide, and no video he posts changes what the drug is. Retatrutide is a promising investigational treatment with strong Phase 2 results and no approval. If it clears Phase 3 review, it will arrive with a brand name, a label, and a prescription — not a discount code.
Frequently Asked Questions
Is Ryan Humiston selling retatrutide?
There is no verified evidence that Ryan Humiston sells retatrutide or owns a company that manufactures it. He is a fitness content creator, and mentions of the drug in his videos reflect commentary rather than a prescription or product recommendation. If you find a website using his name to sell retatrutide, treat it as a marketing tactic and do not buy.
Can you legally buy retatrutide in the US?
No. Retatrutide is an investigational drug that has not been approved by the FDA, so it cannot be legally prescribed or sold for human use in the United States. Products labeled as retatrutide are typically unregulated research chemicals with no guarantee of purity, potency, or sterility.
How effective is retatrutide compared with tirzepatide?
In separate trials, retatrutide produced about 24% average weight loss at 48 weeks at the 12 mg dose, while tirzepatide produced about 21% at 72 weeks. Those trials had different designs and populations, so the numbers are not a direct head-to-head comparison. Tirzepatide is FDA-approved for weight management; retatrutide is not approved.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.